ライフサイエンスコーパス: nanomedicine

1 lete the construction of the multifunctional nanomedicine.

2 and thus may enable practical application in nanomedicine.

3 e fields of catalysis, materials and biology/nanomedicine.

4 r contribute to this groundbreaking field of nanomedicine.

5 abeled drug is spiked into plasma containing nanomedicine.

6 common in biology and is a key challenge in nanomedicine.

7 ong with it, a well-defined set of goals for nanomedicine.

8 goal of safe and effective non-viral genetic nanomedicine.

9 the form of composites or hybrids applied in nanomedicine.

10 hallenges in contemporary bionanoscience and nanomedicine.

11 drug delivery, vaccines, and other areas of nanomedicine.

12 st 5-10 years in polymer-based drug delivery nanomedicine.

13 s in materials chemistry, nanotechnology and nanomedicine.

14 somes in vivo, which may enable personalized nanomedicine.

15 ions show great promise towards personalized nanomedicine.

16 important role in developing next generation nanomedicine.

17 critical task due to their potential use in nanomedicine.

18 e nucleus is imperative for gene therapy and nanomedicine.

19 design of size and charge dual-transformable nanomedicine.

20 cations including catalysis, separation, and nanomedicine.

21 the field of nanoscience, nanotechnology and nanomedicine.

22 rapeutics and next-generation individualized nanomedicine.

23 al in applications including bioanalysis and nanomedicine.

24 route one of the most important targets for nanomedicine.

25 l pathways and has potential applications in nanomedicine.

26 didate in the development of multifunctional nanomedicine.

27 ve important practical implication in future nanomedicine.

28 anoparticle interfaces for implementation in nanomedicine.

29 term impact of microfluidics in the field of nanomedicine.

30 roduction to the field of nanotechnology and nanomedicine.

31 are critical to the advancement of targeted nanomedicine.

32 e egg to break the ill-conceived illusion of nanomedicine.

33 suggest a general strategy for personalized nanomedicine.

34 d approach for addressing a major barrier in nanomedicine.

35 cular target is essential for tumor-targeted nanomedicine.

36 ving therapeutic effectiveness of anticancer nanomedicine.

37 uates new cancer targets for tumor-targeting nanomedicine.

38 e interactions and has broad applications in nanomedicine.

39 tribute to poor intratumoral distribution of nanomedicine.

40 uggesting applications in bioengineering and nanomedicine.

41 of PtNPs and their potential applications in nanomedicine.

42 ssed a three-stage development of UCNP-based nanomedicines.

43 onal approach for developing immune tolerant nanomedicines.

44 available, hampering the development of new nanomedicines.

45 s is critical to the clinical translation of nanomedicines.

46 consumer products, industrial materials, and nanomedicines.

47 direct future formulation design of inhaled nanomedicines.

48 ant step in the (pre)clinical development of nanomedicines.

49 n to improve the pharmacologic properties of nanomedicines.

50 g to exciting progress in the development of nanomedicines.

51 g tumour vessels can improve the delivery of nanomedicines.

52 role of imaging in the future development of nanomedicines.

53 urther improve the targeting efficiencies of nanomedicines.

54 otential dose-dependent in vivo transport of nanomedicines.

55 legant and efficient approach to combination nanomedicines.

56 in adsorption and complement opsonization of nanomedicines.

57 However, the exact mechanism by which nanomedicines accumulate at targeted sites remains a top

58 ly-mediated tumour accumulation of the model nanomedicine adenovirus (Ad) can be substantially enhanc

59 Targeted endothelial nanomedicine agents provide antioxidant, anti-inflammato

60 ables design of diverse targeted endothelial nanomedicine agents.

61 delivery and effect of targeted endothelial nanomedicine agents.

62 sequencing in the case of a combination of a nanomedicine and a targeted therapeutic.

63 ilored applications in the field of sensing, nanomedicine and biochemistry.

64 in the development of innovative methods in nanomedicine and biotechnology.

65 exhibit durable response; the integration of nanomedicine and immunotherapy to address the above chal

66 tein nanomaterials with properties useful in nanomedicine and material science applications.

67 ials with applications in bionanotechnology, nanomedicine and material sciences.

68 challenges and lead to new opportunities in nanomedicine and nanobiotechnology (137 references).

69 The accelerating progress of research in nanomedicine and nanobiotechnology has included initiati

70 lly exaggerated, and the assumptions used in nanomedicine and nanoformulations turned out to be inapp

71 ckaging motor and developments of pRNA-based nanomedicine and nanomaterial.

72 for potential applications in biotechnology, nanomedicine and nanotechnology.

73 implications in the fields of nanomaterial, nanomedicine and nanotoxicology, where assumption of the

74 ticles (NPs) is a paramount question in both nanomedicine and nanotoxicology.

75 ies as well as technological applications in nanomedicine and other fields.

76 s most relevant to the field of non-targeted nanomedicine and presents an account of ligand-targeted

77 ns in material chemistry, nanoscale physics, nanomedicine and structural biology.

78 Overall, light-activated nanomedicines and DDSs are expected to provide more effe

79 ) and its possible use for remote control of nanomedicines and drug delivery systems.

80 ew studies have addressed the combination of nanomedicines and molecular targeted therapeutics.

81 Design of nanomedicines and nanoparticle-based antimicrobial and a

82 rts have been made in developing FR-targeted nanomedicines and nanoprobes and translating them into c

83 on the latest development of folate-mediated nanomedicines and nanoprobes for chemotherapy and diagno

84 rete expectations from the field of targeted nanomedicines and strategies to meet those expectations.

85 be developed which will advance the field of nanomedicines and ultimately improve patient outcomes.

86 ield has been overwhelmed by nanotechnology, nanomedicine, and many nano-sized drug delivery systems.

87 engineering surface properties, biosensing, nanomedicine, and smart materials will widen their appli

88 udied as an important class of components in nanomedicine, and they have been used either alone or in

89 the development and regulatory evaluation of nanomedicines, and aid in determination of generic bioeq

90 t on future development of nanotheranostics, nanomedicines, and chemical technologies.

91 future directions in the area of phage-based nanomedicines, and discuss the state of phage-based clin

92 future development of MSNs-based anti-cancer nanomedicines, and propose several innovative and forwar

93 linical drug development paradigm for cancer nanomedicines, and the further development of chemo-immu

94 e become one of the most promising inorganic nanomedicines, and their biomedical applications have gr

95 romolecules, in particular, those related to nanomedicine applications.

96 for their optimal use in nanotechnology and nanomedicine applications.

97 rapeutic regimen, may constitute a promising nanomedicine approach in cancer therapy.

98 To this end, the nanomedicine approach provides a promising way towards e

99 croenvironment could be modulated by various nanomedicine approaches to overcome hypoxia-associated r

100 Advances in nanomedicine are providing sophisticated functions to pr

101 suggest that smaller ( approximately 12 nm) nanomedicines are ideal for cancer therapy due to their

102 curately predict transvascular permeation of nanomedicines are needed to aid in design optimization.

103 tion of cancer nanomedicines, as most of the nanomedicines are sequestered by nontumor cells.

104 d/or polysaccharides) for the development of nanomedicines are summarized in this review, including t

105 ring, with strong contributions to the whole nanomedicine area.

106 respect to applications in drug delivery and nanomedicine as a result of their biocompatibility and b

107 ected to have broad implications in clinical nanomedicine as alternative vehicles to those involved i

108 Such challenges are not unique to nanomedicine, as they are common in the development of s

109 or implications in the translation of cancer nanomedicines, as most of the nanomedicines are sequeste

110 nic-translational applications of UCNP-based nanomedicines, as well as realization of our "one drug f

111 r understanding of the behavior of any given nanomedicine at the tissue of interest or to understand

112 Thus engineered nanomedicine attain spherical entity with ~90 +/- 6 nm h

113 ify new molecular targets for tumor-targeted nanomedicine based on a quantitative analysis.

114 The development of state-of-art nanomedicines based on mesoporous silica nanoparticles (

115 e describe here a transformable liquid-metal nanomedicine, based on a core-shell nanosphere composed

116 Nanomedicine-based approaches to cancer treatment face s

117 ative assessment of the tumor selectivity of nanomedicine-based systems.

118 seases and summarizes the latest advances in nanomedicine-based therapeutics and theranostics for tre

119 are major biological barriers to translating nanomedicines because they sequester the majority of adm

120 ow these important differences can implicate nanomedicine behavior.

121 he importance of a thorough understanding of nanomedicines' biological performance, ranging from the

122 y developed a novel multivalent METH-binding nanomedicine by conjugating multiple anti-METH scFvs to

123 we explore the role of multifunctionality in nanomedicine by primarily focusing on multistage vectors

124 The nanomedicine can rapidly and effectively release its DOX

125 fined success for the clinically-used cancer nanomedicines can enable the design of next-generation n

126 Current cancer nanomedicines commonly suffer from poor tumor specificit

127 plored to incorporate platinum warheads into nanomedicine constructs.

128 the lessons learned regarding variations in nanomedicine delivery to different tumor types and betwe

129 This unique nanomedicine demonstrates: (i) high drug payload, (ii) d

130 Progress in nanomedicine depends on the development of nanomaterials

131 The effectiveness of nanoparticles (NP) in nanomedicine depends on their ability to extravasate fro

132 tem should be of value to current and future nanomedicine designs.

133 nano-bio interactions, positively impacting nanomedicine development and their regulatory approval.

134 nomedicines, how imaging studies are guiding nanomedicine development, and the role of imaging in the

135 Here we apply accelerated nanomedicine discovery to generate a potential aqueous p

136 Compared to free DOX, the biotin-modified nanomedicine displayed greatly increased cell uptake and

137 vivo experiments have shown that the SQ-Dox nanomedicine dramatically improved the anticancer effica

138 ty, and surface chemistry all play a role in nanomedicine drug delivery.

139 Existing methods to measure nanomedicine drug release in biological matrices are ina

140 tion in plasma, and can be used to calculate nanomedicine encapsulated and unencapsulated drug fracti

141 nanostructures for advanced applications in nanomedicine, energy, chemical sensing, and colloidal pl

142 approaches and advances recently reported in nanomedicine, especially as it pertains to promising vir

143 sult, this new DNA-GNR based multifunctional nanomedicine exerted greatly increased potency (~67 fold

144 , which can be further applied to many other nanomedicine fields.

145 d@C(82)(OH)(22) a potentially more effective nanomedicine for pancreatic cancer than traditional medi

146 show great promise in terms of personalized nanomedicine for patient-specific diagnosis and treatmen

147 e authors will summarize the applications of nanomedicine for RT cancer treatment, and pay particular

148 a detailed investigation of shape effects in nanomedicine for this category of nanostructures.

149 evelop multifunctional and tissue responsive nanomedicines for a broad range of diseases.

150 The contemporary use of nanomedicines for cancer treatment has been largely limi

151 dings provide insights for de novo design of nanomedicines for fatal diseases such as pancreatic canc

152 scular diseases, highlighting the promise of nanomedicines for hyperlipidemic and metabolic syndromes

153 The development of nanomedicines for improved diagnosis and treatment of di

154 pears to be important for the design of safe nanomedicines for inhalation therapy.

155 om the past successes and failures of cancer nanomedicines for its future applications in cancer immu

156 particles and opens a new pathway to develop nanomedicines for many diseases associated with glycocal

157 hybrid prodrug to construct self-deliverable nanomedicines for more effective combination chemotherap

158 riers; and (6) the design of multifunctional nanomedicines for novel combination therapies with suppo

159 h the plasma membrane and the development of nanomedicines for precise delivery to subcellular compar

160 to the normoisotopic drug released from the nanomedicine formulation.

161 They are currently exploited in several nanomedicine formulations.

162 pport the rapid translation of new liposomal nanomedicines from bench to bedside, new cost-effective

163 in many applications in nanoelectronics and nanomedicine, from single molecule sensors to water filt

164 Our objective was to study a radiation nanomedicine (gold nanoseeds) composed of 30-nm gold nan

165 opularity of biomimetic design principles in nanomedicine has led to therapeutic platforms with enhan

166 Nanomedicine has the potential to transform clinical car

167 Proposed nanomedicine has three distinct compartments namely; pol

168 ogress in developing design rules for cancer nanomedicines has been slow, hindering progress in the f

169 The use of nanoparticles in medicine (nanomedicine) has recently become an intensely studied f

170 benefits to intracellular drug delivery from nanomedicine have been limited by biological barriers an

171 Advanced forms of nanomedicine have been synthesized for better pharmacoki

172 Recent advances in the field of nanomedicine have demonstrated that biomimicry can furth

173 of nanoscience and innovative techniques of nanomedicine have moved micro/nanoparticles (MNPs) to th

174 Indeed, advances in nanomedicine have rapidly translated into clinical pract

175 However, few nanomedicines have been successfully translated into cli

176 ng preclinical efficacy results, monotherapy nanomedicines have failed to produce enhanced response r

177 Nanomedicines have provided fresh impetus in the fight a

178 nd, five different types of paclitaxel-based nanomedicine having different polymer stabilizers were e

179 y of alendronic acid with bone, the proposed nanomedicine hold promises in delivering drug to bone mi

180 nd cancer, facilitating the expansion of the nanomedicine horizon.

181 describe recent advances in the labeling of nanomedicines, how imaging studies are guiding nanomedic

182 NP-bacteria mixtures typical in nanomedicine, however, are not yet amendable for direct

183 Here, three clinically relevant nanomedicines, i.e., high-density lipoprotein ([S]-HDL),

184 fined clinical success in the case of cancer nanomedicines: (i) physicochemical design principles, an

185 ug loading and physicochemical properties of nanomedicine in a precise manner through molecular engin

186 ding of the interactions driving the fate of nanomedicine in biological systems remains elusive.

187 One of the main goals of nanomedicine in cancer is the development of effective d

188 zed through a novel near-infrared-responsive nanomedicine in favor of the enhancement of therapy effi

189 The earliest impact of nanomedicine in ophthalmology is likely to involve the a

190 vironment, can severely limit the utility of nanomedicine in the oncological setting.

191 the most recent advances of MSN anti-cancer nanomedicines in enhancing chemotherapeutic efficacy, ov

192 e accumulation of intravenously administered nanomedicines in many pathological tissues.

193 The success of nanomedicines in the clinic depends on our comprehensive

194 Nanomedicines in the sub-100nm range have been suggested

195 enhance the accumulation and penetration of nanomedicines in tumor tissue, we developed and evaluate

196 h opens up a new path for precise control of nanomedicines in vivo.

197 Our results help elucidate nanomedicines' in vivo fate and provide guidelines for e

198 te bacteriophages (phages) can be applied in nanomedicine, in particular, as nanoprobes for precise d

199 These criteria have long been the goal in nanomedicine, in particular, for systemic applications i

200 t candidate target molecules for endothelial nanomedicine includes peptidases and other enzymes, cell

201 irections that are vital to the new field of nanomedicine, including imaging and drug delivery.

202 hage structures in many aspects of precision nanomedicine, including ultrasensitive biomarker detecti

203 nd stable compounds, and visualize how these nanomedicines interact with cognate T cells.

204 for the challenging translation endothelial nanomedicine into the clinical domain.

205 engineered nanomaterials, the translation of nanomedicines into clinic is particularly complex.

206 nds enhances accumulation and penetration of nanomedicines into tumor cell monolayers and spheroids.

207 Nanomedicine is a burgeoning industry but an understandi

208 iological processes that dictate the fate of nanomedicine is integral to developing more effective in

209 n of such size and charge dual-transformable nanomedicine is rarely reported.

210 osurgery strategies where a high uptake of a nanomedicine is required for effective and timely treatm

211 distribution and fate of emerging classes of nanomedicine is scarce.

212 A compelling vision in nanomedicine is the use of self directed nanoparticles t

213 hallenging and clinically important goals in nanomedicine is to deliver imaging and therapeutic agent

214 Now, the "holy grail" in nanomedicine is to design and synthesize new advanced ma

215 The rational design of nanomedicines is a challenging task given the complex ar

216 tform for next-generation organelle-specific nanomedicines is also provided.

217 Development of well-defined nanomedicines is critical for their successful clinical

218 of GOx and l-Arg, a novel glucose-responsive nanomedicine (l-Arg-HMON-GOx) has been for the first tim

219 we will briefly discuss L-NV applications in nanomedicine, looking also for their future perspectives

220 well as the development of a new paradigm in nanomedicines - (low molecular weight) drug-free macromo

221 With recent advances in the field of nanomedicine, many new strategies have emerged for diagn

222 However, advances in nanomedicine may now help the vast potential of RNAi the

223 re relevant to nanoelectromechanical system, nanomedicine, microfluidics and lab-on-a-chip architectu

224 tudies indicate that our overall approach of nanomedicine needs serious reevaluation.

225 ades have witnessed the rapid development of nanomedicine (NM) which integrates the advancement of va

226 on using multifunctional hybrid nanogels in nanomedicine, not only as drug carriers but also as imag

227 One-component nanomedicine (OCN) represents an emerging class of thera

228 nd key considerations for rational design of nanomedicine of synergistic drug combinations for cancer

229 Nanomedicine of synergistic drug combinations has shown

230 cept in the field of drug delivery to obtain nanomedicines of high drug loading and high reproducibil

231 Nanomedicine offers unique advantages in treating human

232 mpact of sequencing of such therapeutics and nanomedicines on the antitumor outcome.

233 ion density) and identification of a ternary nanomedicine optimized to overcome important siRNA deliv

234 Nanomedicine, particularly liposomal drug delivery, has

235 of chemical sensing, biosensing, bioimaging, nanomedicine, photocatalysis and electrocatalysis.

236 This report represents a novel nanomedicine platform combining up-regulation of tumoral

237 In this work, we present a nanomedicine platform to counteract plaque development b

238 The development of nanomedicines presents the potential to deliver more pot

239 These nanomedicines promote the differentiation of disease-pri

240 The lessons learned from these nanomedicines provide an important insight into the key

241 ze and charge; it offers effective and rapid nanomedicine purification with high lipid recovery (> 98

242 or in biological specimens for toxicology or nanomedicine purposes.

243 and may have broad applications in personal nanomedicine ranging from imaging and photo-destruction

244 Here, we formulated a targeted nanomedicine, rapamycin encapsulated in pegylated octade

245 roughout the paper, we will share some novel nanomedicine related ideas and insights that were derive

246 Successful bench-to-bedside translation of nanomedicine relies heavily on the development of nanoca

247 However, current nanomedicine research has been focused on the delivery o

248 very and toxicity are critical issues facing nanomedicine research.

249 xploited for targeted delivery of anticancer nanomedicines resulting in numerous pharmaceutical produ

250 Despite nanomedicine's remarkable potential and growth over the

251 tem is a prerequisite for the realization of nanomedicine's translational promise.

252 In the field of nanomedicine, selective delivery to cancer cells is a co

253 armaceutical excipients and its formulation (nanomedicine) should have good manufacture processes wit

254 Ten pMHCII-based nanomedicines show similar biological effects, regardles

255 This nanomedicine shows prolong stability in serum and delive

256 urthermore, we highlight the next generation nanomedicine strategies based on this novel chemistry.

257 ibing the current state-of-the-art regarding nanomedicine strategies in PDT, with a comprehensive nar

258 gy, there have been great interests in using nanomedicine strategies to enhance radiation responses o

259 Promising advances in nanomedicine such as magnetic hyperthermia rely on a pre

260 pplications in which the MPhi is loaded with nanomedicines, such as liposomes ex vivo, so when the dr

261 eveloped as a high-efficiency antithrombotic nanomedicine targeted for collagen exposed on diseased b

262 eractions and developing immune-smart cancer nanomedicine that can take advantage of the body's immun

263 sponse against cancer is an emerging area of nanomedicine that has the potential to redefine the way

264 Nanomedicine that is able to target and deliver therapeu

265 Unlike traditional carrier-based nanomedicines that are inherently multicomponent systems

266 nes can enable the design of next-generation nanomedicines that can address some of the emerging chal

267 ns, and astrocytes) for different disorders, nanomedicines that can enable targeting of specific cell

268 progress towards effective oral delivery of nanomedicines that can overcome the intestinal epithelia

269 ders and to highlight the recent advances in nanomedicines that can target specific disease-associate

270 Nanomedicines that co-deliver DNA, RNA, and peptide ther

271 Nanomedicines that preferentially deploy cytotoxic agent

272 ixarenes might have in bionanotechnology and nanomedicine, that are especially related to their combi

273 Nanomedicine, the application of nanotechnology to medic

274 This tumor-targeted, tocotrienol-based nanomedicine therefore significantly improved the therap

275 novesicles can represent a paradigm shift in nanomedicine: they may complement liposomes, showing the

276 pMHCII-based nanomedicines thus represent a new class of drugs, poten

277 Here we apply targeted nanomedicine to achieve in vivo cell-mediated tissue rep

278 e, we summarized some strategies employed in nanomedicine to achieve specific cell targeting or to en

279 discuss the potential of these properties in nanomedicine to down-regulate inflammatory pathways or t

280 h imaging, and this requires labeling of the nanomedicine to enable detection outside the body.

281 Nanomedicine to overcome both systemic and tumor tissue

282 dvancement of nanotechnology, development of nanomedicines to efficiently target dysfunctional macrop

283 s demonstrate the potential of antimicrobial nanomedicines to simplify MTB drug regimens.

284 ntial for application in areas as diverse as nanomedicine, to food technology and industrial catalysi

285 been the main impetus behind the progress of nanomedicines towards the clinic.

286 To optimally exploit nanomedicines, understanding their biological behavior i

287 w cytometry to evaluate the biodistribution, nanomedicines' uptake by plaque-associated macrophages/m

288 n liposomes have emerged as one of the first nanomedicines used clinically for localized delivery of

289 des, resulting in several approved liposomal nanomedicines used in the clinic.

290 In-vitro bone targeting efficiency of nanomedicine was studied using hydroxyapatite crystals a

291 ouse osteosarcoma confirm the selectivity of nanomedicine when compared to its internalization in non

292 n vivo requires development of more advanced nanomedicines, where synthesis of multifunctional polyme

293 This technological revolution has led way to nanomedicine, which spurred the development of clever dr

294 ssel is seldom the target tissue, almost all nanomedicine will interact with blood vessels and blood

295 ribes the current and future perspectives of nanomedicine with particular emphasis on the clinical ta

296 nted nanoemulsions as anti-COX-2 theranostic nanomedicine with possible anticancer applications.

297 Liposomes are a promising class of nanomedicine with the potential to provide site-specific

298 We engineered nanomedicine with the stealth corona made up of densely

299 ition; (2) scalable approaches for producing nanomedicines with optimized bioavailability and excreti

300 or future applications in nanotechnology and nanomedicine, with the focus on development of sensors t